15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience

International Journal of Radiation Oncology Biology Physics

Volumn 67, Issue 1, 2007, Pages 57-64

  Sylvester, John E ^a   Grimm, Peter D ^a   Blasko, John C ^a   Millar, Jeremy ^b   Orio III, Peter F ^c   Skoglund, Scott ^a   Galbreath, Robert W ^d,e   Merrick, Gregory ^d  

^a Seattle Prostate Institute   (United States)

^b William Buckland Radiotherapy Centre   (Australia)

^c UNIVERSITY OF WASHINGTON   (United States)

^d WHEELING JESUIT UNIVERSITY   (United States)

^e Ohio University Eastern   (United States)

Author keywords

Brachytherapy; Long term results; Prostate cancer

Indexed keywords

BIOCHEMISTRY; PATHOLOGY; PATIENT TREATMENT; RADIOTHERAPY; REGRESSION ANALYSIS; RISK ASSESSMENT;

BRACHYTHERAPY; HIGH-RISK GROUP; LONG-TERM RESULTS; PROSTATE CANCER;

TUMORS;

BIOCHEMICAL MARKER; IODINE 125; PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER LOCALIZATION; CANCER SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RELAPSE; RISK ASSESSMENT; SCORING SYSTEM;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BRACHYTHERAPY; COHORT STUDIES; DISEASE-FREE SURVIVAL; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PALLADIUM; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOISOTOPES; RADIOTHERAPY, ADJUVANT;

EID: 33845599085     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.07.1382     Document Type: Article

References (37)

1. Sylvester J., Blasko J.C., Grimm P., et al. Interstitial implantation techniques in prostate cancer. J Surg Oncol 66 (1997) 65-75
2. Grimm P.D., Blasko J.C., and Ragde H. Ultrasound-guided transperineal implantation of Iodine-125 and Palladium-103 for the treatment of early-stage prostate cancer: Technical concepts in planning, operative technique, and evaluation. In: Schellhammer P.F. (Ed). New techniques in prostate surgery, vol 2 (1994), Saunders Co, Philadelphia, W.B 113-126
3. Sylvester J., Blasko J., and Grimm P. Transrectal ultrasound guided prostate brachytherapy image guided diagnosis and treatment of cancer. In: D'Amico A., Loeffler J.S., and Harris J.R. (Eds). Image-guided diagnosis and treatment of cancer (2003), Humana Press, Totowa 119-154
4. Merrick G.S., Wallner K., Butler W.M., et al. A comparison of radiation dose to the bulb of the penis in men with and without prostate brachytherapy-induced erectile dysfunction. Int J Radiat Oncol Biol Phys 50 (2001) 597-604
5. Hilaris B., Fuks Z., Nori D., et al. Interstitial irradiation in prostatic cancer: Report of 10-year results. In: Rolf S. (Ed). Interventional radiation therapy techniques/brachytherapy (1991), Springer-Verlag, Berlin 235
6. Stock R.G., Stone N.N., Tabert A., et al. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 41 (1998) 101-108
7. Potters L., Cao Y., Calugaru E., et al. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 50 (2001) 605-614
8. Grimm P., Blasko J., Sylvester J.E., et al. 10-year biochemical (prostate-specific antigen) control of prostate cancer with 125-I brachytherapy. Int J Radiat Oncol Biol Phys 51 (2001) 31-40
9. Blasko J.C., Grimm P.D., Sylvester J.E., et al. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 46 (2000) 839-850
10. Potters L., Cha C., Oshinsky G., et al. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy. Cancer J Sci Am 5 (1999) 301-306
11. Dattoli M., Wallner K., True L., et al. Prognostic role of serum prostatic acid phosphatase for 103Pd-based radiation for prostatic carcinoma. Int J Radiat Oncol Biol Phys 45 (1999) 853-856
12. Ragde H., Elgamal A.A., Snow P.B., et al. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma [Review]. Cancer 83 (1998) 989-1001
13. Stock R.G., and Stone N.N. The effect of prognostic factors on therapeutic outcome following transperineal prostate brachytherapy. Semin Surg Oncol 13 (1997) 454-460
14. Beyer D.C., and Priestley J.B. Biochemical disease-free survival following I-125 prostate implantation [Abstract]. Int J Radiat Oncol Biol Phys 32 Suppl (1995) 254
15. Sylvester J., Blasko J.C., Grimm P.D., et al. Neoadjuvant androgen ablation combined with external beam radiation therapy and permanent interstitial brachytherapy boost in localized prostate cancer. Mol Urol 3 (1999) 231-236
16. Sylvester J., Blasko J.C., Grimm P.D., et al. Short-course androgen ablation combined with external-beam radiation therapy and low-dose-rate permanent brachytherapy in early-stage prostate cancer: A matched subset analysis. Mol Urol 4 (2000) 155-159 discussion 161
17. Merrick G.S., Butler W.M., Galbreath R.W., et al. Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer. Int J Radiat Oncol Biol Phys 51 (2001) 41-48
18. Lederman G.S., Cavanagh W., Albert P.S., et al. Retrospective stratification of a consecutive cohort of prostate cancer patients treated with a combined regimen of external-beam radiotherapy and brachytherapy. Int J Radiat Oncol Biol Phys 49 (2001) 1297-3003
19. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Clinical utility of percent-positive prostate biopsies in predicting biochemical outcome after radical prostatectomy or external-beam radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 18 (2000) 1164-1172
20. Zelefsky M.J., Fuks Z., Hunt M., et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166 (2001) 876-881
21. Sylvester J.E., Blasko J.C., Grimm P.D., et al. Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: The Seattle experience. Int J Radiat Oncol Biol Phys 57 (2003) 944-952
22. Thames H., Kuban D., Levy L., et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys 57 (2003) 929-943
23. Steinberg D.M., Sauvageot J., Piantadosi S., et al. Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol 21 (1997) 566-576
24. Epstein J.L. Gleason score 2-4 adenocarcinoma of the prostate on needle biopsy: A diagnosis that should not be made. Am J Surg Pathol 24 (2000) 477-478
25. Roehl K.A., Han M., Ramos C.G., et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: Long term results. J Urol 172 (2004) 910-914
26. Ung J.O., Richie J.P., Chen M.H., et al. Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. Urology 60 (2002) 458-463
27. Kupelian P.A., Buchsbaum J.C., Elshaikh M.A., et al. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: Year of treatment an independent predictor of outcome. Int J Radiat Oncol Biol Phys 57 (2003) 629-634
28. Han M., Partin A.W., Pound C.R., et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retroprubic prostatectomy. The 15-year John Hopkins experience. Urol Clin North Am 28 (2001) 555
29. Pound C.R., Partin A.W., Eisenberger M.A., et al. The natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591
30. Gancarcyzk K.J., Wu H., McLeod D.G., et al. Using the percentage of positive biopsy cores for cancer, pretreatment PSA and highest biopsy Gleason sum to predict pathologic stage after radical prostectomy: The center for prostate disease research nomograms. Urology 61 (2003) 589-595
31. Merrick G.S., Butler W.M., Wallner K.E., et al. Prognostic significance of percent positive biopsies in clinical organ confined prostate cancer treatment with permanent prostate brachytherapy with or without supplemental external beam radiation therapy. Cancer J 10 (2004) 54-60
32. Merrick G.S., Butler W.M., Wallner K.E., et al. Extracapsular radiation dose distribution after permanent prostate brachytherapy. Am J Clin Oncol 26 (2003) e178-e189
33. Merrick G.S., Butler W.M., Wallner K.E., et al. Impact of supplemental external beam radiotherapy and/or androgen deprivation on biochemical outcome after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 61 (2005) 32-43
34. Stone N.N., Stock R.G., and Unger P. Intermediate term biochemical-free progression and local control following 125-Iodine brachytherapy for prostate cancer. J Urol 173 (2005) 803-807
35. 103 brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer: A 12-year experience from a single group practice. Brachytherapy 4 (2005) 33-44
36. Critz F.A., and Levinson K. 10-year disease-free survival rates after simultaneous irradiation for prostate cancer with a focus on calculation methodology. J Urol 172 (2004) 2232-2238
37. Han M., Partin A.W., Zahurak M., et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169 (2003) 517-523